Leadership,Planning, andEvaluation

Linda L. Tanzer

April 26, 2023

RUTGERS

Cancer Institute of New Jersey
RUTGERS HEALTH











Consistent, Experienced, Dedicated Leadership



Libutti
Center Director
6 Years CINJ
Leadership



White
Deputy Director
27 Years CINJ
Leadership



Hochster

AD Clinical
Research
5 Years CINJ
Leadership



Ganesan

AD Translational
Research

10 Years CINJ
Leadership
(18 yrs CINJ)



Senior Leadership will incorporate internal and external advice to develop a Strategic Plan, collaborate to implement strategies to accomplish its goals and objectives, and continuously evaluate its progress.



Kang

AD Consortium
Research

5 Years CINJ
Leadership



Lattime

AD Education/
Training

25 Years CINJ
Leadership



Tanzer

AD Administration/
Planning

21 Years CINJ
Leadership
(30 yrs CINJ)

■ New Senior Leaders



Shen

AD Basic

Research

16 Years CINJ

PrgLdr, Asst Dir

Basic Research



Kinney
AD Population
Science and
Community
Outreach
(new position)
4 Years CINJ
Leadership and
at CINJ



Berger
AD Shared
Resources
(new position)
3 Years CINJ
Leadership and
at CINJ



In

AD Diversity,
Equity, and
Inclusion
(new position)

1 Year CINJ
Leadership and
at CINJ

Mission

Senior Leadership will incorporate internal and external advice to develop a Strategic Plan, collaborate to implement strategies to accomplish its goals and objectives, and continuously evaluate its progress.

Effective Internal Advisory and Evaluation Committees



Internal Advisory Board (IAB)
Chair Joseph Barone (Dean, Rutgers
Ernest Mario School of Pharmacy)



- Laid groundwork for modified SOPs related to joint recruitment with RU Schools
- Investment from RU for recruitment of outstanding tenure track faculty
- Support for market-driven compensation changes to enhance retention




Consortium Steering Committee (CSC)
Chair Yibin Kang

Examples of IMPACT in this grant period:

- PU faculty now represented in all Research Programs
- Targeted cancer-focused researchers in PU faculty recruitment efforts
- Promoted shared resources, resulting in increased use of Biostatistics, Genome Editing, Biospecimen Repository/Histopathology, and others by PU investigators
- Implemented an annual Consortium symposium with trainee presentations across scientific disciplines

Oversight of CCSG-related Activities



Research Leadership Council

- Composed of Program Leaders and ADs
- Oversees the research base/membership, collaborations, translation, developmental funds, and infrastructure

Examples of IMPACT

- New Cancer Prevention and Outcomes Data Support Shared Resource
- Reorganized Comprehensive Genomics to increase access to the newest technologies
- Increased Catchment Area Responsive Research

Effective External Advisory Board

External Advisory Board (EAB)



Chair Candace Johnson (President & CEO, Roswell Park Comprehensive Cancer Center)

Recommendation

- Provide pilot funds to seed P01s and SPOREs (2019)
- RU and RWJBH must continue support of CINJ beyond the fiveyear commitment made in 2017 (2019, 2020)
- Hone scientific goals to capitalize upon the distinctive strengths of Members and resources (2019)
- Incentivize IIT development (e.g., Institutional support); provide LOI and protocol writing support (2019)
- CINJ is located in a hub (pharma/biotech) for translation/commercialization; apply strategic focus to optimizing opportunities (2019, 2021)

Action

- Seeded two P01 applications (one funded [Shen et al., P01CA250957] and an NCI/CRUK award
- Institutional Commitment has doubled since 2018
- New Strategic Plan goals, \$28 million investment, reflect signature initiative in immunology and metabolism
- AD for Clinical Research receives annual institutional support to fund IITs; LOI and protocol writing support provided by Center Administration
- Molloy appointed as first AD for BioPharma Alliances in Oncology

Effective Community Bi-Directional Communication

Community Cancer Action Board - NEW

Chair Dorothy Reed (President, Sister2Sister Network)

Composition: Community Thought Leaders, Patient Advocates



Examples of IMPACT in this Grant Period

- Helped identify CINJ's CA priority cancers and risk factors
- Engaged in bidirectional communication with CINJ researchers
- Strategic Plan Vision, Values, and Goals/Objectives enhanced to reflect commitment to inclusivity, diversity, NJ communities

Revised Vision Statement

Through our science, our evidencebased actions, our openness, and our respect for those we serve, we will advance cancer-focused research worldwide and reduce the burden of cancer in our catchment area.

By engaging with, empowering, and addressing the questions and fears of our exceptionally diverse populations, we will engender hope for cancer patients and their families and play a critical role in strengthening the fabric of our communities by gaining and protecting their trust and providing access to the outstanding oncology care each person deserves.

■ Impact of Senior Leader Collaboration



New five-year Strategic Plan



Programmed new facility



Recruited ADs. developed Offices of DEI and SRM



↑ in interventional treatment study accrual with statewide impact







Dramatically expanded cancer screening for underserved CA regions



Promoted cancer focus and collaboration among the membership, increasing all KPIs




Growth in signature efforts in Immunology and Metabolism

Impactful Leadership Collaborations: Translational Research

Developed and implemented a plan to increase translational research

- Provided access to complete, deidentified counts of genomics available at CINJ and RWJBH network
- Implemented Organoid Development Service
- Created Division of Oncologic
 Pathology to optimize recruitment of research-focused pathologists
- Recruited faculty in high priority areas, e.g., neuro, Phase I
- Appointed Clinical Research
 Oversight Committee to determine center-wide, data-driven priorities
- Appointed OHRS Medical Directors



- Provided annual budget to develop translatable concepts into clinical trials, including CETI projects
- Reorganized and increased CPDM staff
- Consolidated IRB activities under WIRB

■ A Living Document



- Living document, adjusted to adapt to:
 - Changes/challenges
 - CA needs
 - Extraordinary opportunities
- Guides annual goal setting, budget
- Progress reviewed annually



Goal 1

Conduct exceptional, innovative, and collaborative research through Research Programs that reflect scientific vision, demonstrate excellence, and strive to make an impact on our catchment area.



Owner*
Eileen White
Deputy Director

Goal 1

Conduct exceptional, innovative, and collaborative research through Research Programs that reflect scientific vision, demonstrate excellence, and strive to make an impact on our catchment area.



Owner*
Eileen White
Deputy Director

Objective 1.1

Continue to establish itself as a national leader in metabolism and immunology research.

Goal 1

Conduct exceptional, innovative, and collaborative research through Research Programs that reflect scientific vision, demonstrate excellence, and strive to make an impact on our catchment area.



Owner*
Eileen White
Deputy Director

Objective 1.1

Continue to establish itself as a national leader in metabolism and immunology research.

Strategy 1.1.1


Recruit outstanding scientists.

Strategy 1.1.2

Develop shared resources.



Progress 40%



O1.1: Become national leader in metabolism and immunology research



Recruit Nine Outstanding Faculty 2020-2025

- Hinrichs
- Payne
- Lim 🕏
- Skinnider §
- 2 add'l Sr recruits in final stages 🕏
- 2 add'l mid-level over next two years
- 2 add'l Jr over next two years \$\forall



Develop Shared Resources

- Metabolomics: New Instrumentation, Staff
- Immune Monitoring and Flow Cytometry
- GMP Facility



Thank You

Q&A Segment

RUTGERS

Cancer Institute of New Jersey **RUTGERS HEALTH**







